-
-
Liquid biopsy offers many advantages over tissue biopsy, but it is currently limited to advanced cancer patients. We believe that improving sensitivity is the top priority for enhancing the clinical impact of liquid biopsy.
Background noise is the biggest cause of the sensitivity limitations in liquid biopsy. Despite numerous efforts to eliminate background noise, most have not been significantly effective.
We engineered a DNA polymerase directly involved in gene amplification to develop the ADPS smart DNA Polymerase, which is equipped with discrimination capability. ADPS is a cancer diagnosis platform technology that combines unique primer-probe design, maximizing the ultra-high sensitivity and specificity of this innovative DNA polymerase, with buffer optimization technology.
ADPS achieves high sensitivity
that enables the diagnosis of
patients with MAF of up to 0.01%.
It enables treatment decisions for patients with early-stage cancer as well as advanced cancer.
Various nucleic acid biomarkers such as DNA, GC-rich DNA, methylated DNA, and RNA can be detected,
and all types of cancer mutations can be identified simply by modifying the primer-probe design.
Even the primer-probe design alone can detect all types of cancer mutations.
We developed the ADPS Oncogene Mutation Test
that achieves a detection sensitivity of
up to 0.01% by applying the ADPS technology.
